Your browser doesn't support javascript.
loading
Commercial Chinese polyherbal preparation Zao Ren An Shen prescription for primary insomnia: a systematic review with meta-analysis and trial sequential analysis.
Zhao, Fei-Yi; Xu, Peijie; Kennedy, Gerard A; Zheng, Zhen; Zhang, Wen-Jing; Zhu, Jia-Yi; Ho, Yuen-Shan; Yue, Li-Ping; Fu, Qiang-Qiang; Conduit, Russell.
Afiliación
  • Zhao FY; Department of Nursing, School of International Medical Technology, Shanghai Sanda University, Shanghai, China.
  • Xu P; Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
  • Kennedy GA; School of Computing Technologies, RMIT University, Melbourne, VIC, Australia.
  • Zheng Z; Institute of Health and Wellbeing, Federation University, Ballarat, VIC, Australia.
  • Zhang WJ; School of Health and Biomedical Sciences, RMIT University, Melbourne, VIC, Australia.
  • Zhu JY; Institute for Breathing and Sleep, Austin Health, Heidelberg, VIC, Australia.
  • Ho YS; School of Health and Biomedical Sciences, RMIT University, Melbourne, VIC, Australia.
  • Yue LP; Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
  • Fu QQ; Yangpu Hospital, School of Medicine, Tongji University, Shanghai, China.
  • Conduit R; School of Nursing, Faculty of Health and Social Sciences, The Hong Kong Polytechnic University, Kowloon, China.
Front Pharmacol ; 15: 1376637, 2024.
Article en En | MEDLINE | ID: mdl-38957383
ABSTRACT

Background:

Natural products are widely used for primary insomnia (PI). This systematic review with trial sequential analysis (TSA) aimed to summarize evidence pertaining to the effectiveness and safety of Zao Ren An Shen (ZRAS) prescription, a commercial Chinese polyherbal preparation, for treating PI.

Methods:

Controlled clinical trials appraising ZRAS compared to controls or as an add-on treatment were systematically searched across seven databases until January 2024. Cochrane ROB 2.0 and ROBINS-I tools were adopted to determine risk of bias. Quality of evidence was assessed using the GRADE framework.

Results:

We analyzed 22 studies, involving 2,142 participants. The effect of ZRAS in reducing Pittsburgh Sleep Quality Index scores was found to be comparable to benzodiazepines [MD = 0.39, 95%CI (-0.12, 0.91), p = 0.13] and superior to Z-drugs [MD = -1.31, 95%CI (-2.37, -0.24), p = 0.02]. The addition of ZRAS to hypnotics more significantly reduced polysomnographically-recorded sleep onset latency [MD = -4.44 min, 95%CI (-7.98, -0.91), p = 0.01] and number of awakenings [MD = -0.89 times, 95%CI (-1.67, -0.10), p = 0.03], and increased total sleep time [MD = 40.72 min, 95%CI (25.14, 56.30), p < 0.01], with fewer adverse events than hypnotics alone. TSA validated the robustness of these quantitative synthesis results. However, the quality of evidence ranged from very low to low. The limited data available for follow-up did not support meta-synthesis.

Conclusion:

While ZRAS prescription shows promising effectiveness in treating PI, the overall quality of evidence is limited. Rigorously-designed randomized control trials are warranted to confirm the short-term efficacy of ZRAS and explore its medium-to-long-term efficacy. Systematic Review Registration (https//www.crd.york.ac.uk/prospero/display_record.php?RecordID=471497), identifier (CRD42023471497).
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Front Pharmacol Año: 2024 Tipo del documento: Article País de afiliación: China Pais de publicación: Suiza
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Front Pharmacol Año: 2024 Tipo del documento: Article País de afiliación: China Pais de publicación: Suiza